Search clinical trials for: TERN-701

Total 289 results

Terns, Inc.

Not yet recruiting

CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, Chronic Phase

United States
Terns, Inc.

Completed

DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis

NASH - Nonalcoholic Steatohepatitis

United States
Cephalon

Completed

Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis

Psoriasis

United States
Cephalon

Completed

Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation

Leukemia, Myeloid
Terns, Inc.

Completed

AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis

NASH - Nonalcoholic Steatohepatitis

United States
TWi Biotechnology, Inc.

Completed

Prophylactic Treatment of Skin Rash Associated With EGFR Inhibitor Therapy

EGFR Inhibitor-Induced Skin Rash

Taiwan
Ronald Hoffman
National Cancer Institute (NCI); Myeloproliferative Disorders-Research Consortium

Unknown

CEP-701 (Lestaurtinib) in Myelofibrosis

Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis

United States
Terns, Inc.

Completed

LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)

NASH - Nonalcoholic Steatohepatitis

United States
Amgen

Withdrawn

A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ProxiMMity-1)

Relapsed/Refractory Multiple Myeloma
BioMarin Pharmaceutical

Terminated

BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study)

Late-onset Pompe Disease

United States, United Kingdom, Germany, France, Italy, Portugal, Belgium, Netherlands
Amgen

Available

AMG 701 Expanded Access Program
BioMarin Pharmaceutical

Completed

Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease

Pompe Disease

United States, United Kingdom, France, Australia, Germany
BioMarin Pharmaceutical

Terminated

Extension Study for Patients Who Have Participated in a BMN 701 Study

Pompe Disease

United States, United Kingdom, Australia, France, Germany, New Zealand
Millennium Pharmaceuticals, Inc.

Completed

Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies

Advanced Solid Tumors

United States
University of Leeds
Spinal Injury Rehabilitation Center

Completed

TEleRehabilitation Nepal (TERN) to Improve Quality of Life of People With Spinal Cord Injury and Acquired Brain Injury (TERN)

Spinal Cord Injuries; Traumatic Brain Injury; Acquired Brain Injury, Stroke

Nepal
New Approaches to Neuroblastoma Therapy Consortium
National Cancer Institute (NCI)

Completed

N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma

Neuroblastoma

United States, Canada
Karen Ballen, MD

Recruiting

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MF and CMML (HSCT 002)

Acute Myeloid Leukemia | Myelofibrosis | Chronic Myelomonocytic Leukemia

United States
Bellicum Pharmaceuticals

Terminated

Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Uveal Melanoma

United States
Cephalon

Terminated

Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma

Myeloma

United States
University of Rochester
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Recruiting

Imaging of Lymphatic Vessels in People With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

United States
National Cancer Institute (NCI)

Recruiting

Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

Neuroendocrine Tumors | Carcinoma, Neuroendocrine | Neuroendocrine Carcinomas | Carcinoma, Adrenal Cortical | Carcinoma, Adrenocortical

United States
Cephalon

Completed

Study of CEP-701 in Treatment of Prostate Cancer

Prostate Cancer

United States
Trius Therapeutics LLC

Completed

Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections

Skin Diseases, Infectious | Skin Diseases, Bacterial

United States
University of Rochester
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Completed

NIR Fluorescence Imaging of Lymphatic Transport Using ICG (NIR-ICG)

Rheumatoid Arthritis

United States
Karolinska Institutet
Doctors For You

Recruiting

Effect of Trauma Life Support Training Programs on Patient Outcomes

Trauma Injury

India
Corbus Pharmaceuticals Inc.
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Recruiting

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Solid Tumor, Adult

United States, Spain, Turkey, United Kingdom
Trius Therapeutics LLC

Completed

Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate

Healthy

United States
University of Nebraska

Withdrawn

Increasing Physical Activity of Patients With Head and Neck Cancer (I-PAP Study) (I-PAP)

Head and Neck Cancer

United States
Inozyme Pharma

Recruiting

The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency (ENERGY)

Generalized Arterial Calcification of Infancy | Autosomal Recessive Hypophosphatemic Rickets | Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency

United States, United Kingdom
Inozyme Pharma

Recruiting

Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency

Generalized Arterial Calcification of Infancy | Autosomal Recessive Hypophosphatemic Rickets | Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency

United States, United Kingdom, Canada, France, Germany
Inozyme Pharma
IQVIA Biotech

Active, not recruiting

Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE

Pseudoxanthoma Elasticum | Generalized Arterial Calcification of Infancy | ATP-Binding Cassette Subfamily C Member 6 Deficiency

United States, United Kingdom
Epizon Pharma, Inc.

Completed

A Clinical Trial of Epizon-701 (EPN-701) in Subjects With End-Stage Renal Disease (ESRD)

End-Stage Renal Disease (ESRD)

United States
M.D. Anderson Cancer Center
Cephalon

Completed

CEP-701 for PH-negative Myelofibrosis

Leukemia | Myelofibrosis

United States
Inozyme Pharma

Recruiting

The SEAPORT 1 Study: Evaluation of the Safety and Tolerability of INZ-701 in Adults With End-Stage Kidney Disease Undergoing Hemodialysis

Calciphylaxis

United States
Chong Kun Dang Pharmaceutical

Completed

A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration

Neovascular(Wet) Age Related Macular Degeneration

Korea, Republic of
Trius Therapeutics LLC

Completed

Microdialysis and Pharmacokinetic Study of TR-701

Healthy

United States
Mersin University

Completed

The Effect of Acupressure Applied to Menopausal Women on Menopausal Symptoms and Quality of Life

Quality of Life | Menopausal Symptom

Turkey
The Taub Group

Completed

The Safety and Efficacy of Naltrexone and Scopolamine Utilized in the Treatment of Major Depression

Depression

United States
Trius Therapeutics LLC

Completed

A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response

Healthy Subjects

United States
Trius Therapeutics LLC

Completed

A Pharmacokinetics and Safety Study in Subjects With Renal Impairment

Renal Impairment

United States
Shire

Completed

Intensive Pharmacovigilance Program for Elaprase (SHP ELA-701)

Hunter Syndrome

Mexico
Johnson & Johnson Pharmaceutical Research & Development...
Janssen-Cilag Ltd.

Completed

A Research Study to Evaluate the Safety of R306465, a Drug in Development for Cancer and to Study the Absorption, Break Down and Elimination in Patients With Advanced Solid Malignancies.

Neoplasms
Trius Therapeutics LLC

Completed

TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Skin and Subcutaneous Tissue Bacterial Infections

United States, Argentina, Australia, Brazil, Germany, Mexico, New Zealand, Poland, Russian Federation, South Africa, Spain
University of Rochester

Completed

Near InfraRed Fluorescence Using Indocyanine Green and Magnetic Resonance Lymphography of Lymphatic Transport (NIR-ICG MRL)

Rheumatoid Arthritis

United States
Trius Therapeutics LLC

Completed

Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg

Bacterial Infection

United States
University of California, San Francisco

Completed

Study Of PHarmacogenetics in Ethnically Diverse Populations (SOPHIE Study) (SOPHIE)

Focus Groups

United States
Massachusetts General Hospital
The Salah Foundation; MGH cure ALS Fund

Completed

A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States
Medtronic Cardiac Rhythm and Heart Failure
Medtronic

Completed

PREFER (Pacemaker Remote Follow-Up Evaluation and Review)

Bradycardia | Arrhythmia

United States
Blueprint Medicines Corporation

Terminated

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Neoplasms | Respiratory Tract Diseases | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | Non Small Cell Lung... and other conditions

United States
Trius Therapeutics LLC

Completed

Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients

Bacterial Infection

Search clinical trials for: TERN-701

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations